Insider Buying: CapsoVision (NASDAQ:CV) Major Shareholder Purchases 13,850 Shares of Stock

Posted by George Bondi on Jul 8th, 2026

CapsoVision, Inc. (NASDAQ:CV – Get Free Report) major shareholder Eliyahou Et Al Harari bought 13,850 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were acquired at an average cost of $7.35 per share, for a total transaction of $101,797.50. Following the purchase, the insider directly owned 3,200,751 shares in the company, valued at $23,525,519.85. This trade represents a 0.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

CapsoVision Price Performance

CV stock opened at $5.67 on Wednesday. CapsoVision, Inc. has a 1-year low of $3.43 and a 1-year high of $15.37. The business has a 50 day simple moving average of $6.90 and a two-hundred day simple moving average of $6.79. The company has a market capitalization of $283.27 million and a price-to-earnings ratio of -2.42.

CapsoVision (NASDAQ:CV – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $2.79 million for the quarter.

Institutional Investors Weigh In On CapsoVision

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CV. Deutsche Bank AG bought a new stake in shares of CapsoVision in the 4th quarter valued at approximately $47,000. Wells Fargo & Company MN raised its holdings in CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after buying an additional 2,508 shares during the period. Virtu Financial LLC bought a new stake in CapsoVision in the fourth quarter worth $128,000. Millennium Management LLC purchased a new position in CapsoVision during the fourth quarter worth $163,000. Finally, Bank of America Corp DE increased its position in CapsoVision by 528.9% during the first quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock valued at $162,000 after acquiring an additional 18,702 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CV shares. Benchmark dropped their price target on CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating for the company in a research note on Friday, March 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

View Our Latest Analysis on CapsoVision

CapsoVision Company Profile

(Get Free Report)

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.